Lodenafil

Source: Wikipedia, the free encyclopedia.
Lodenafil
Clinical data
Trade namesHelleva
Pregnancy
category
  • Not for use in women
Routes of
administration
By mouth
Legal status
Legal status
  • In general: unscheduled
Identifiers
  • 5-(2-Ethoxy-5-{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}phenyl)-1-methyl-3-propyl-1,4-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
JSmol)
  • CCCc1c2c(c(=O)nc([nH]2)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)CCO)n(n1)C
  • InChI=1S/C23H32N6O5S/c1-4-6-18-20-21(27(3)26-18)23(31)25-22(24-20)17-15-16(7-8-19(17)34-5-2)35(32,33)29-11-9-28(10-12-29)13-14-30/h7-8,15,30H,4-6,9-14H2,1-3H3,(H,24,25,31) ☒N
  • Key:NEYKRKVLEWKOBI-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)
Lodenafil carbonate

Lodenafil (also known as hydroxyhomosildenafil, trade name Helleva) is a drug belonging to a class of drugs called PDE5 inhibitor, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. Like udenafil and avanafil it belongs to a new generation of PDE5 inhibitors.

Lodenafil is formulated as a

dimer, lodenafil carbonate, which breaks down in the body to form two molecules of the active drug lodenafil. This formulation has higher oral bioavailability than the parent drug.[1]

It is manufactured by Cristália Produtos Químicos e Farmacêuticos in Brazil and sold there under the brand-name Helleva.[2]

It has undergone Phase III clinical trials,

U.S. Food and Drug Administration
.

See also

References

  1. S2CID 29575687
    .
  2. ^ Cristália Archived 2015-03-15 at the Wayback Machine Product page. Retrieved on September 16, 2009.
  3. PMID 19040623
    .
  4. .